Provenge

Showing 15 posts of 17 posts found.

dendreon image

Another NICE no for Dendreon cancer drug

January 13, 2015
Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T

Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …

Dendreon image

Dendreon files for bankruptcy

November 12, 2014
Research and Development, Sales and Marketing Dendreon, Provenge, awick, delaware, johnson, nj

Dendreon Corporation, the troubled manufacturer of high-cost cancer vaccine Provenge, has filed for bankruptcy as a prelude to restructuring its …

NICE not recommending Dendreon cancer vaccine

October 16, 2014
Sales and Marketing Dendreon, NHS, NICE, Provenge, sipuleucel-T, therapeutic cancer vaccine

NICE has issued preliminary draft guidance not recommending Dendreon’s therapeutic cancer vaccine Provenge for prostate cancer in people whose disease …

John Johnson image

Dendreon chief resigns from struggling firm

June 10, 2014
Medical Communications, Sales and Marketing Cancer, Dendreon, John Johnson, Provenge, Vaccine, Watson, prostate

Chief executive of Dendreon John Johnson is to step down in the summer amid falling sales of the company’s key …

dendreon image

Dendreon slashes more jobs

November 13, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Dendreon, Provenge, cuts

Another 150 jobs are to go at Dendreon Corporation as the company seeks to cut $125 million per year in …

Dendreon slashes staff and closes facility

July 31, 2012
Manufacturing and Production, Sales and Marketing Dendreon, M&P, Provenge, prostate cancer

Cancer vaccine specialist Dendreon has said it will slash 600 jobs and close one of its three manufacturing facilities in …

screen_shot_2012-07-05_at_11

New chairman of the board for Dendreon

July 5, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dendreon, Provenge, johnson, prostate cancer

Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the …

Zytiga image

Janssen looks to broaden Zytiga licence

June 18, 2012
Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate

Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …

Zytiga image

Strong Zytiga study results could increase uptake

March 12, 2012
Research and Development, Sales and Marketing IDMC, Janssen, Provenge, Zytiga, prostate

Janssen’s prostate cancer pill Zytiga could be on course to target a larger number of patients following a positive late-stage …

Slow Provenge growth prompts Dendreon staff cull

September 13, 2011
Business Services, Manufacturing and Production Dendreon, Provenge, job cuts, pharma manufacturing news

After months of building manufacturing capacity, US biotech Dendreon has decided to slash a quarter of its workforce – with …

Dendreon drops GSK as Provenge manufacturing partner

September 8, 2011
Manufacturing and Production Dendreon, GSK, Provenge, pharma manufacturing news

Dendreon has called a halt to its manufacturing and supply deal with GlaxoSmithKline for cancer vaccine Provenge, citing “delays and …

Dendreon wins green light for Provenge production

March 22, 2011
Manufacturing and Production Cancer, Dendreon, FDA, Provenge, pharma manufacturing, prostate cancer vaccine, sipuleucel-T

US oncology specialist Dendreon has been boosted by the approval of additional production capacity for its therapeutic prostate cancer vaccine …

Dendreon will outsource first Provenge production in EU

January 11, 2011
Manufacturing and Production Dendreon, Provenge, cancer vaccine, contract manufacturing, sipuleucel-T, vaccine manufacturing, vaccines

US oncology specialist Dendreon has decided to hire a contract manufacturer for its cell-based cancer therapy Provenge in Europe to …

Dendreon eyes late 2011 European cancer vaccine filing

January 10, 2011
Sales and Marketing Cancer, Denreon, Provenge, cancer vaccine, sipuleucel, vaccines

Dendreon Group is to seek marketing authorisation in Europe for the world’s first immunotherapy cancer vaccine in late 2011 or …

Latest content